Evolent Health, Inc. Cash and Equivalents

Quick Answer

Evolent Health, Inc. reported Cash and Equivalents of $151.86 million for fiscal year 2025.

Evolent Health, Inc. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $151.86M +45.7%
2024 $104.20M -46.0%
2023 $192.82M +2.5%
2022 $188.20M -29.3%
2021 $266.28M -16.5%
2020 $319.00M +215.8%
2019 $101.01M -55.8%
2018 $228.32M -4.2%
2017 $238.43M +77.2%
2016 $134.56M -7.7%
2015 $145.73M
2014 $0.00
2013 $0.00 -100.0%
2012 $5.25M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2025 $116.65M +20.8% -22.7%
June 30, 2025 $151.00M +49.1% -38.8%
March 31, 2025 $246.55M +49.3% +136.6%
December 31, 2024 $104.20M -46.0% +7.9%
September 30, 2024 $96.58M -47.7% -4.6%
June 30, 2024 $101.25M -29.0% -38.7%
March 31, 2024 $165.15M +4.8% -14.4%
December 31, 2023 $192.82M +2.5% +4.5%
  • Evolent Health, Inc. showed an increase of +45.7% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2012–2025 period, Evolent Health, Inc.’s cash and equivalents has grown by 2791.4% (from $5.25 million to $151.86 million).
  • The most recent figure is from Evolent Health, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment